Get the Stockscreener App
1.46
5.04%
0.07
After Hours:
1.48
0.02
+1.37%
Invivyd Inc stock is traded at $1.46, with a volume of 2.73M.
It is up +5.04% in the last 24 hours and up +12.31% over the past month.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
See More
Previous Close:
$1.39
Open:
$1.48
24h Volume:
2.73M
Relative Volume:
1.00
Market Cap:
$412.89M
Revenue:
$53.43M
Net Income/Loss:
$-52.49M
P/E Ratio:
-4.068
EPS:
-0.3589
Net Cash Flow:
$-58.29M
1W Performance:
+7.35%
1M Performance:
+12.31%
6M Performance:
-5.19%
1Y Performance:
+176.20%
1-Day Range:
$1.435
$1.545
1-Week Range:
$1.3663
$1.575
52-Week Range:
$0.483
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.46 | 393.10M | 53.43M | -52.49M | -58.29M | -0.3589 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
View All
Invivyd Inc Stock (IVVD) Latest News
Invivyd gives 17 new hires options to buy 731,000 shares - Stock Titan
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Invivyd appoints Michael Mina as chief medical officer By Investing.com - Investing.com India
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances - Investing.com
Invivyd Ends King & Spalding Lobbying Engagement After Three Weeks - Legis1
Invivyd (IVVD) price target increased by 25.00% to 10.20 - MSN
Invivyd (IVVD) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
IVVD Price Today: Invivyd, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Invivyd rises after update from late-stage trial for COVID therapy - MSN
Biotech Biz Moves Into Ex-Bank Site - New Haven Independent
Invivyd Shareholder Action Reminder - TMX Newsfile
Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Invivyd, Inc. draws on 73 years of DNA innovation to guide viral research - Traders Union
Invivyd (IVVD) Announces Favorable Phase 3 Analysis for VYD2311 COVID-19 Treatment - Yahoo Finance
10 Best NASDAQ Growth Stocks to Buy and Hold Forever - Insider Monkey
Is Invivyd (IVVD) stock overvalued today | Invivyd Inc posts narrower loss, EPS beats estimates by 55.2%Analyst Ratings - Cổng thông tin điện tử tỉnh Lào Cai
Invivyd Inc posts narrower loss, EPS beats estimates by 55.2%Real Time Stock Idea Network - Xã Châu Thành
Invivyd Inc stock (US46186M1080): Is its monoclonal antibody strategy strong enough for COVID market - AD HOC NEWS
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit - The Manila Times
Invivyd chair joins Mehmet Oz, Mark Cuban at POLITICO health event - Stock Titan
Invivyd Inc stock (US46186M1080): Is its monoclonal antibody edge strong enough for COVID market rec - AD HOC NEWS
Invivyd stock surges as FDA alignment boosts COVID-19 program - MSN
Aug Reactions: What are Invivyd Incs technical support levelsLayoff News & Expert-Curated Trade Recommendations - baoquankhu1.vn
Invivyd: Why The Trial Upsizing Isn't The Green Light Bulls Think It Is (NASDAQ:IVVD) - Seeking Alpha
Authentic virus research in labs faces adaptation hurdles, Invivyd, Inc. asserts - Traders Union
Invivyd unveils measles monoclonal antibody candidate VMS-063 - BioWorld News
H.C. Wainwright reiterates Invivyd stock rating on measles program By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Invivyd stock rating on measles program - Investing.com
Invivyd upsizes COVID-19 trial, targets measles antibody By Investing.com - Investing.com Australia
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody CandidateSlideshow (NASDAQ:IVVD) 2026-04-09 - Seeking Alpha
Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063 - MarketBeat
Invivyd stock surges 25% on COVID-19 trial progress By Investing.com - Investing.com Australia
Invivyd reveals plans to test an antibody drug against measles - BioPharma Dive
Invivyd posts update from late-stage COVID trial (IVVD:NASDAQ) - Seeking Alpha
Invivyd stock surges 25% on COVID-19 trial progress - Investing.com
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):